Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure

@article{Investigators1993EffectOR,
  title={Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure},
  author={Therapy Study Investigators},
  journal={The Lancet},
  year={1993},
  volume={342},
  pages={821-828}
}
View on Elsevier
doi.org
779 Citations
Highly Influential Citations
8
Background Citations
38
Methods Citations
10
Results Citations
4

779 Citations

Citation Type

Citation Type

Effect of ramipril on morbidity and mode of death among survivors of acute myocardial infarction with clinical evidence of heart failure. A report from the AIRE Study Investigators.
TLDR
Ramipril reduces mortality and progression to resistant heart failure among patients with evidence of heart failure early after myocardial infarction and appears to be a major factor contributing to the reduction in mortality both by reducing circulatory failure and by reducing sudden death.
Long-term survival benefit of ramipril in patients with acute myocardial infarction complicated by heart failure
TLDR
For patients with clinically defined heart failure following AMI, ramipril results in a sustained survival benefit, and is associated with an extension of life of up to 14.5 months for, on average, 13 months treatment duration.
ACE inhibitors in heart failure: effect on mode of death.
  • W. Kübler
  • Medicine, Biology
    European heart journal
  • 1997
TLDR
A comprehensive meta-analysis for all completed, published or unpublished randomized, placebo-controlled trials of ACE inhibitors revealed a significant reduction in total mortality and in the combined endpoint of mortality and hospitalization for congestive heart failure and similar benefits were observed with different ACE inhibitors.
evidence from the AIRE study heart failure after acute myocardial infarction : variables in patients with clinical evidence of Blocker treatment and other prognostic β
TLDR
Blocker treatment is associated with improved outcomes in patients with clinical evidence of mild to moderate heart failure after myocardial infarction, and highrisk patients with persistent heart failure appear to benefit at least as much as lower risk patients with transient heart failure.
Prevention of Congestive Heart Failure by ACE Inhibition in Patients with Acute Myocardial Infarction
TLDR
It is indicated that patients with symptomatic or asymptomatic left ventricular dysfunction after an acute myocardial infarction should receive long-term treatment with an ACE inhibitor and that such treatment may improve survival, reduce the incidence of overt heart failure and reduce the risk of reinfarction.
Effect of angiotensin converting enzyme inhibition after acute myocardial infarction in patients with arterial hypertension
TLDR
A retrospective analysis of data from the Trandolapril Cardiac Event study found that ACE inhibition after AMI complicated with left ventricular dysfunction was of greater benefit to patients with a history of arterial hypertension.
Effect of the angiotensin-converting enzyme inhibitor trandolapril on mortality and morbidity in diabetic patients with left ventricular dysfunction after acute myocardial infarction
β Blocker treatment and other prognostic variables in patients with clinical evidence of heart failure after acute myocardial infarction: evidence from the AIRE study
Objectives To examine clinical outcomes associated with optional β blockade in a population of patients with evidence of heart failure after myocardial infarction. Design and patients Data from the…
Pharmacotherapy following myocardial infarction - a review of current treatment practices
Modern treatment of acute myocardial infarction (AMI), including thrombolysis and early interventional strategies, has reduced mortality rates but increased the number of patients requiring medical…
Inhibition of the renin-angiotensin system after acute myocardial infarction—treat first, select later?
TLDR
Strong advocates have emerged for a compromise strategy in which treatment of most patients with suspected myocardial infarction is initiated early, continued for a short period of time, and then withdrawn except when clinical heart failure or an ejection fraction of less than 40% is observed, but this article caution against such an approach.
...
1
2
3
4
5
...